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Abstract
Aim: To investigate the influence of metformin use on liver dysfunction and hepatic encephalopathy in a retrospective
cohort of diabetic cirrhotic patients. To analyze the impact of metformin on glutaminase activity and ammonia production
in vitro.
Methods: Eighty-two cirrhotic patients with type 2 diabetes were included. Forty-one patients were classified as insulin
sensitizers experienced (metformin) and 41 as controls (cirrhotic patients with type 2 diabetes mellitus without metformin
treatment). Baseline analysis included: insulin, glucose, glucagon, leptin, adiponectin, TNFr2, AST, ALT. HOMA-IR was
calculated. Baseline HE risk was calculated according to minimal hepatic encephalopathy, oral glutamine challenge and
mutations in glutaminase gene. We performed an experimental study in vitro including an enzymatic activity assay where
glutaminase inhibition was measured according to different metformin concentrations. In Caco2 cells, glutaminase activity
inhibition was evaluated by ammonia production at 24, 48 and 72 hours after metformina treatment.
Results: Hepatic encephalopathy was diagnosed during follow-up in 23.2% (19/82): 4.9% (2/41) in patients receiving
metformin and 41.5% (17/41) in patients without metformin treatment (logRank 9.81; p = 0.002). In multivariate analysis,
metformin use [H.R.11.4 (95% CI: 1.2–108.8); p = 0.034], age at diagnosis [H.R.1.12 (95% CI: 1.04–1.2); p = 0.002], female sex
[H.R.10.4 (95% CI: 1.5–71.6); p = 0.017] and HE risk [H.R.21.3 (95% CI: 2.8–163.4); p = 0.003] were found independently
associated with hepatic encephalopathy. In the enzymatic assay, glutaminase activity inhibition reached 68% with
metformin 100 mM. In Caco2 cells, metformin (20 mM) decreased glutaminase activity up to 24% at 72 hours post-
treatment (p,0.05).
Conclusions: Metformin was found independently related to overt hepatic encephalopathy in patients with type 2 diabetes
mellitus and high risk of hepatic encephalopathy. Metformin inhibits glutaminase activity in vitro. Therefore, metformin use
seems to be protective against hepatic encephalopathy in diabetic cirrhotic patients.
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Introduction
Hepatic encephalopathy (HE) is one of the major complications
of liver cirrhosis affecting one third of cirrhotic patients [1]. It has
relevant socio-economic impact since HE reduces quality-of-life
and is associated with higher mortality rate [2]. HE occurs as a
result of the coexistence of hyperammonemia and inflammation in
patients with liver dysfunction and/or porto-systemic shunts [3].
Ammonia production takes place mainly in the small intestine
where glutaminase type K activity is crucial for the pathogenesis of
HE [4]. Type 2 diabetes mellitus and insulin resistance (IR) are
characterized by the release of pro-inflammatory cytokines, such
as TNFa and IL-6, resulting in an inflammatory state [5]. Diabetes
has been independently related to control of active variceal
bleeding [6] and is associated with an increased risk of
hepatocellular carcinoma development [7]. Type 2 diabetes
mellitus has also been found associated with hepatic encephalop-
athy in patients with HCV-related cirrhosis [8]. Insulin sensitizers,
like metformin, decrease insulin secretion and reduce hyperinsu-
linemic state. Metformin increases beta oxidation and reduces the
hepatic gluconeogenesis via activation of AMP-K pathway;
decreases intestinal glucose absorption and increases glucose
uptake in skeletal muscle [9]. Recently, it has been found able to
modulate the expression of cytokines, such as TNFa [10]. Thus,
IR state could influence hepatic encephalopathy development in
patients with cirrhosis. Insulin-sensitizers seem to decrease HCC in
patients with cirrhosis C [11]. Therefore, the ammonia produc-
tion, IR and the pro-inflammatory state seem to trigger cirrhosis
PLOS ONE | www.plosone.org 1 November 2012 | Volume 7 | Issue 11 | e49279
progression, and may be interesting as therapeutic targets in the
near future, improving the prognosis of cirrhotic patients.
The aim of this study was to determine whether the metformin
use was associated with decreased risk of hepatic encephalopathy
in diabetic cirrhotic patients and to analyze the ability of
metformin to inhibit glutaminase activity in vitro.
Methods
Patients
Eighty-two consecutive diabetic cirrhotic patients from the Unit
for Clinical Management of Digestive Diseases, University
Hospital of Valme, were included. The study started either with
the first visit to Hepatology office or with the first hospital
admission and outcomes to finish were survival and liver
transplantation. Exclusion criteria were: age#18 years; non-
diabetic patients; patients with type 1 diabetes mellitus; and
patients with treatment ongoing for cirrhosis. The protocol was
approved by the CEIC of University Hospital of Valme (Sevilla,
Spain) and all patients provided written informed consent to
participate in this study. The study was conducted in accordance
with the ethical guidelines of the Declaration of Helsinki and
International Conference on Harmonization Guidelines for Good
Clinical Practice. A total of 41 cases and 41 controls were
included. They were classified according to insulin sensitizers
experienced. Cases were defined as patients who underwent
metformin treatment, while controls were defined as cirrhotic
patients with type 2 diabetes mellitus without metformin
treatment. Metformin-experienced average time was 33.4626.7
months. Type 2 diabetes mellitus was diagnosed according to the
American Diabetes Association [12].
Biochemical and Clinical Parameters
Baseline analysis, using commercial tests, included: insulin,
glucose, glucagon, TNFr2, leptin, adiponectin, AST and ALT.
HOMA-IR was calculated [glucose (mmol/L) * Insulin (IU/ml)/
Table 1. Comparison of baseline characteristics between groups.
MET group (n = 41) Non-MET group (n = 41) Significance
Age (years) 60.269 60.4610 0.908
Sex, males 34 (82.9%) 28 (68.3%) 0.123
Child-Pugh score 5.961.0 6.361.6 0.194
MELD score 9.062.4 9.964.2 0.285
Etiology of cirrhosis 0.476
Alcohol 26 (63.4%) 20 (48.8%)
HCV 9 (22%) 13 (31.7%)
HBV 1 (2.4%) 1 (2.4%)
Autoimmune 0 (0%) 2 (4.9%)
Others 5 (12.2%) 5 (12.2%)
HOMA-IR 8.365.2 6.764.3 0.203
Insulin (mU/mL) 24.2616.7 19.5612.9 0.231
Glucose (mmol/L) 8.565.4 9.363.4 0.619
Glucagon (pg/mL) 101.2645.5 111.9666 0.547
TNFr2 (pg/mL) 14.368.9 18.267.7 0.203
Leptin (ng/mL) 20.2616.6 20616.9 0.977
Adiponectin (mg/L) 12.763.4 17.6611.7 0.159
AST (IU/L) 55.1663.8 44.3625.8 0.553
ALT (IU/L) 43.6643.9 45.3645.3 0.905
Ascites 7 (17.1%) 18 (43.9%) 0.008
Variceal bleeding 5 (12.2%) 6 (14.6%) 0.746
Follow-up (months) 39.6628.3 45.4626.5 0.344
doi:10.1371/journal.pone.0049279.t001
Table 2. Univariate analysis between hepatic
encephalopathy and outcomes.
Hepatic
encephalopathy Significance
Metformin use 0.002 (Log Rank 9.81)
Yes 4.9% (2/41)
No 41.5% (17/41)
GLS gene alteration 0.018 (Log Rank 5.57)
Yes 21.4% (6/28)
No 45.4% (10/22)
Altered OGC & MHE 0.006 (Log Rank 7.57)
Yes 45.8% (11/24)
No 19.2% (5/26)
GLS: glutaminase. OGC: oral glutamine challenge. MHE: minimal hepatic
encephalopathy.
doi:10.1371/journal.pone.0049279.t002
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22,5]. Cirrhosis was defined and based on liver biopsy, ultrasound,
endoscopic analysis and biochemical parameters.
Encephalopathy Management
Minimal hepatic encephalopathy (MHE) was diagnosed based
on psychometric hepatic encephalopathy score (PHES) and critical
flicker frequency (CFF) (HepatonormTM Analyzer (R&R Medi-
Business Freiburg GmbH, Freiburg, Germany)). This battery
comprises the digit symbol test (DST), the number connection test
A (NCT-A), the number connection test B (NCT-B), the serial
dotting test (SDT), and the line drawing test (LDT). Patients were
classified as having MHE when the PHES score was less than 24
points or the CFF value was below the cut-off (38 Hz) [13]. For
oral glutamine challenge (OGC) analysis, blood samples were
taken at baseline and 60 minutes following glutamine load (10 g
glutamine dissolved in 100 ml water (L-Glutamine, SHS S.A.,
Spain)). Ammonia was measured using the DaFonseca-Whollheim
method in an auto-analyzer (Hitachi 911; Roche Diagnostics,
Mannheim, Germany). A pathological response curve for gluta-
mine tolerance was defined as an ammonia rise to .128 mg/dL at
60 minutes after the glutamine intake [14]. Genetic studies
included length of microsatellites in the 59UTR region of
glutaminase gene together with haplotype TACC, as previously
described [15]. Baseline high risk for hepatic encephalopathy was
defined according to MHE, altered OGC and genetic alterations.
Patients with MHE (PHES,24 or CFF,38 Hz) and altered
OGC (NH3.128 mg/dl at 60 minutes) or showing genetic
(Large/large microsatellite or non-TACC haplotype) were classi-
fied as high risk of HE development (48%; 24/50) and the rest
(52%; 26/50) as low risk of overt HE.
Experimental Study
We performed an experimental study in vitro (chemical assay
and cells assay) to investigate the glutaminase activity inhibition,
according to different metformin concentrations.
First, in an enzymatic assay, we tested different metformin doses
(0, 10, 25, 50 and 100 mM) with a constant glutamine
concentration (100 mM). Ammonia production was measured to
determine the glutaminase activity.
On the other hand, human colonic epithelial mammalian cell
line of Caco2 (American Type Culture Collection, ATCC) was
maintained in DMEM medium pH 7.4 supplemented with 10%
fetal bovine serum, 2.2 g/L HCO3Na, 100 mM sodium pyruvate,
Figure 1. Kaplan Meier curve showing the impact of metformin use on hepatic encephalopathy (n = 82; log Rank: 9.45; p = 0.002).
doi:10.1371/journal.pone.0049279.g001
Table 3. Multivariate analysis according to overt HE.
Hepatic encephalopathy Multivariate
Metformin use [H.R. 11.4 (95% CI: 1.2–108.8); p = 0.034]
Age at diagnosis [H.R. 1.12 (95% CI: 1.04–1.2); p = 0.002]
Female sex [H.R. 10.4 (95% CI: 1.5–71.6); p = 0.017]
HE risk [H.R. 21.3 (95% CI: 2.8–163.4); p = 0.003]
doi:10.1371/journal.pone.0049279.t003
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0.292 gr/L glutamine, 100 U/mL penicillin, 100 mg/mL strepto-
mycin and 0.25 mg/mL amphotericin in 5% CO2 at 37uC. Cell
assay was initiated 24 hr after seeding. Caco2 cells (10000 cells/
cm2) were cultured in presence of different metformin doses (0, 20,
50, 100 and 200 mM) and samples (cell pellet and cultured
medium) were collected after 0, 24, 48 and 72 hr post-treatment.
Glutaminase activity was determined by the measurement of
ammonia production.
Statistical Analysis
Results are expressed as mean6SD of 3 independent experi-
ments. Data were compared using ANOVA with the Least
Significant Difference (LSD) test as posthoc multiple comparison
analysis. We used the Kaplan-Meier method (log rank test to
compare curves), Chi-square and T-student. Cox’s regression was
used for univariate analysis and those variables with p,0.150 were
entered into the multivariate analysis. The statistical differences
were placed at p#0.05.
Results
Effect of Metformin Use on Hepatic Encephalopathy
Baseline epidemiological, biochemical and liver function test
from both groups of patients are shown in Table 1. No differences
were found in sex, age, etiology of cirrhosis and liver function
(including Child-Pugh score and MELD). The etiology of cirrhosis
was alcoholic cirrhosis (n = 46; 56.1%), HCV-related (n = 22;
26.8%), HBV-related (n = 2; 2.4%), cryptogenic (n = 10; 12.3%) or
autoimmune (n = 2; 2.4%). Gender distribution was 75.6% men
(62/82) and 24.4% females (20/82), with mean age of 60.369.5
years. Liver function according to Child-Pugh stage was: 57
patients (69.5%) at Child-Pugh Stage A; 24 patients (29.3%) at
Stage B and 1 patient (1.2%) at stage C. Mean Child-Pugh score
was 6.161.4 and MELD score was 9.563.5. Average follow-up
was 42.5627.4 months. Nineteen patients (23.2%) developed
episodes of overt HE during follow-up. These bouts were related
to diuretics (31.6%; 6/19), variceal bleeding (26.2%; 5/19) and
infections (15.8%; 3/19), being 26.4% (5/19) spontaneous.
Univariate analysis demonstrated altered Child-Pugh, OGC,
PHES, CFF, genetic factors and metformin use were associated
with the risk of overt hepatic encephalopathy (Table 2). In the
metformin group, we found 4.9% of cases (2/41), while 41.5%
(17/41) occurred in controls (log Rank 9.81; p = 0.002) (Fig. 1). In
multivariate analysis, metformin use [H.R. 11.4 (95% CI: 1.2–
108.8); p = 0.034], age at diagnosis [H.R. 1.12 (95% CI: 1.04–1.2);
p = 0.002], female sex [H.R. 10.4 (95% CI: 1.5–71.6); p = 0.017]
and HE risk [H.R. 21.3 (95% CI: 2.8–163.4); p = 0.003] were
found independently associated with EH (Table 3). On the other
hand, overall survival rate reached a trend in cirrhotic patients
metformin-experienced: 92.7% (38/41) of MET group survived
and 82.9% (34/41) of controls.
Effect of Metformin on High Risk Patients
Patients with MHE (PHES,24 or CFF,38 Hz) and altered
OGC (NH3.128 mg/dl at 60 minutes) or showing genetic profile
(Large/large microsatellite or non-TACC haplotype) were classi-
fied as high risk of HE development. Metformin use, in these
cohorts, was associated with lower HE bouts, both in high-risk and
low risk patients (log Rank 7.57; p = 0.006).
Effect of Metformin on Glutaminase Activity in vitro
In chemical assay, 17.5% of glutaminase activity inhibition was
obtained with a metformin concentration of 10 mM and up to
68% inhibition was reached using 100 mM. Therefore, a dose-
dependent glutaminase activity was observed with metformin use
(Fig. 2). In Caco2 cells, 20 mM of metformin showed 24%
inhibition of glutaminase activity at 72 hours compared with the
control at the same time (p,0.05) (ammonia production was
decreased from 26.8560.74 mM to 19.962.05 mM; p,0.05)
(Fig. 3A). Other metformin concentrations (50, 100 and
200 mM) inhibited also the glutaminase activity, but this effect
was lower than 20 mM of metformin, as reflected by the presence
of ammonium in cultured medium (Fig. 3B).
Discussion
The major findings from this work are: first, in the experimental
study, we obtained a partial inhibition of glutaminase activity
(about 20%), both in the chemical and cells assays when compared
with control experiments. Glutaminase converts glutamine in
glutamic acid, which is indispensable for cell function, together
with ammonia and free radicals. Therefore, this partial inhibition
Figure 2. Glutaminase activity in chemical assay (%), according to metformin concentration. Each bar represents the mean6SD (all
experiments were conducted by triplicate).
doi:10.1371/journal.pone.0049279.g002
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is probably enough to prevent complications in cirrhotic patients
(in particular hepatic encephalopathy), preserving the beneficial
effects of glutaminase. Second, we observed an eight-fold lower
risk of hepatic encephalopathy in metformin-experienced patients
(4.9% vs 41.5%; p = 0.002), despite both cohort were similar in
liver function and HE risk score. Metformin effects on glutaminase
activity and inflammatory state (modulated by glycemic control)
could explain, at least in part, this result. HOMA-IR correlates
with protein-C-reactive activity and patients receiving metformin
showed a trend to lowering TNFr2 levels than non-metformin
treated patients (data not shown). Interestingly, in Child-Pugh A
patients, HOMA index was independently associated with higher
rate of overt HE, supporting the hypothesis that insulin resistance
syndrome could promote inflammation and increased risk of overt
HE. Indeed, fecal calprotectin correlated with critical flicker
frequency and HE grading [16].
Type 2 diabetes mellitus has been found associated with hepatic
encephalopathy in patients with Hepatitis C-related cirrhosis. The
mechanisms by which diabetes could promote hepatic encepha-
lopathy includes: a) inflammation states in cirrhotic patients has
been associated with bacterial translocation, hepatic encephalop-
athy and risk of spontaneous bacterial peritonitis. Insulin resistance
syndrome and type 2 diabetes mellitus are considered as an
inflammatory state due to increased production of pro-inflamma-
tory cytokines, such as TNFa and IL-6 [17]; b) motility
impairment has been described in diabetic patients showing
delayed duodenum-cecal transit time. It could promote small
intestine bacterial overgrowth (SIBO) raising bacterial transloca-
tion rate. Indeed, SIBO was found in more than 60% of cirrhotic
patients and it was strongly related to bacterial translocation [18].
Moreover, lactulose breath test was found altered in 8 out of 9
patients with previous bouts of hepatic encephalopathy; c) type 2
diabetes seems to play a role modulating several isoforms of
glutaminase (GA). Three glutaminase isoforms have been
described; kidney-type (KGA), liver-type (LGA) and type C
(CGA). Baglietto-Vargas et al. demonstrated that KGA and
LGA are present in endocrine pancreas (KGA in alpha cells and
periphery of the islets and LGA in beta cells) and could have some
Figure 3. Effect of metformin on glutaminase activity in vitro. 3A) Glutaminase activity inhibition in cells assay (%), according to metformin
concentration; 3B) Ammonia concentration in cells assay, according to metformin concentration. Each bar represents the mean6 SD (all experiments
were conducted by triplicate). *p#0.05 vs. the corresponding control sample. #p#0.05 vs. the same group collected at the previous time point.
doi:10.1371/journal.pone.0049279.g003
Metformin Inhibits Glutaminase Activity
PLOS ONE | www.plosone.org 5 November 2012 | Volume 7 | Issue 11 | e49279
role in the secretion of insulin [19]. In addition, type 2 diabetes
promotes renal uptake of plasma glutamine for the production of
urinary ammonia, activating KGA. Besides, streptozotocin-
induced diabetic rats have demonstrated that hepatocytes use
glutamine more rapidly than do hepatocytes from normal rats; as a
consequence of that, glutaminase activity in diabetic rats is
increased leading to a higher glutamine uptake and ammonia
production. Furthermore, Watford et al. observed the increase in
glutaminase activity in the small intestine in type 2 diabetes rats
[20].
The effect of metformin on hepatic encephalopathy was
stronger than expected. In spite of all these data support an active
effect of metformin on cirrhotics, a selection bias could not be
excluded in a retrospective analysis. Moreover, although metfor-
min seems to be safer than exogenous insulin preventing cirrhosis
complications, it may be difficult to maintain adequate blood
glucose levels with insulin sensitizers alone. Thus, a balance
between glucose control to avoid diabetes progression and insulin
sensitivity to avoid cirrhosis complications is required. Other
cirrhosis outcomes, particularly ascites, were also modified by
metformin use (probably due to decrease inflammation [21]) but in
a different manner and were beyond the aim of our study.
In conclusion, our results indicated that metformin use reduced
the risk of hepatic encephalopathy in diabetic cirrhotic patients,
probably by two mechanisms: inhibiting partially glutaminase
activity and improving insulin sensitivity. A randomized control
trial is warranted to confirm or not these data defining the
usefulness of metformin in the management of liver cirrhosis.
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